Perimenopause and Libido: An Honest Guide to What Changes and What Helps

54% of women experiencing perimenopause symptoms report that it had an impact on their sex life or relationships. Almost none of them have a safe, informed space to work through it. This is that space.

Changes to desire, arousal, and physical comfort during perimenopause are both extremely common and almost entirely absent from public conversation. Women experience them acutely. They rarely speak about them — not to partners, not to GPs, not to friends. The silence creates isolation and frequently creates a narrative that is both painful and incorrect: that something has fundamentally gone wrong with the woman, or with her relationship, or with both.

Neither is true. What has changed is the hormonal environment, and the hormonal environment has changed in ways that have specific, well-understood effects on sexual response. Those effects can, in most cases, be addressed — but addressing them requires knowing what is happening and being willing to raise it with appropriate clinical support.

The Physical Mechanisms

The changes to libido and sexual response during perimenopause are not primarily psychological in origin. They have clear hormonal drivers that produce physiological changes, and understanding those drivers is essential context for managing them.

Oestrogen maintains the health of vaginal and vulval tissue — its thickness, elasticity, lubrication, and the richness of blood supply to the area. When oestrogen declines during perimenopause, this tissue changes. It becomes thinner, less elastic, and less well-supplied with blood. The natural lubrication that was previously reliable becomes less predictable or less adequate. Sensation may change — sometimes reduced, sometimes altered in quality. And for many women, penetrative sex begins to be uncomfortable or painful in ways it was not previously, due to the changes in vaginal tissue health and the reduction in natural lubrication.

This cluster of changes has a clinical name: genitourinary syndrome of menopause, or GSM. It is distinct from the broader concept of low libido, though the two often coexist. GSM is specifically the physical changes to genitourinary tissue driven by oestrogen decline — and it is important to understand that it tends to worsen over time without treatment, unlike hot flushes which typically improve as the hormonal transition completes.

Testosterone drives desire, arousal, and sexual motivation in women, as well as in men. Women produce testosterone in the ovaries and adrenal glands throughout their lives, and its decline during perimenopause has a direct effect on the frequency and intensity of sexual desire, on the ease of arousal, and on sexual enjoyment. Many women describe the testosterone-related change as a reduction not in their capacity for desire but in its spontaneous quality: they may still respond to sexual stimulus, but the unprompted, autonomous experience of wanting sex that characterised their earlier experience has diminished or disappeared.

Spontaneous Versus Responsive Desire

This distinction — between spontaneous and responsive desire — is one of the most important concepts in women's sexual health, and one of the least communicated. Understanding it changes how women interpret their own sexual experience during perimenopause, often significantly for the better.

Spontaneous desire is the experience of sexual wanting that arises without any specific external stimulus — the experience of wanting sex before any sexual context has been established. This is the form of desire that dominates early in adult sexual experience for many women, and it is the form that most cultural narratives and most clinical discussions of libido assume.

Responsive desire is the experience of sexual interest that emerges in response to sexual stimulus — after intimacy has begun, after physical contact, after an erotic context has been established. The wanting emerges from the situation rather than preceding it. Research in women's sexual response, particularly by Rosemary Basson and colleagues, has established that responsive desire is the primary or dominant mode for many women throughout their adult lives — not a deficit or dysfunction, but a different mode of experiencing desire that is entirely healthy and normal.

During perimenopause, many women whose desire was previously spontaneous find that it shifts toward responsive desire — or that spontaneous desire, which was already primarily responsive, becomes more fully so. The experience of never feeling like having sex before intimacy has begun, combined with a cultural and relational expectation that desire should be spontaneous, creates a situation where many women conclude they have low libido when in fact they have responsive desire that is not being recognised or accommodated.

This distinction matters enormously. If your partner initiates intimacy and you do not feel desire before you engage, but find that desire does emerge once you are engaged — your libido is responsive, not absent. That is a different situation from the absence of desire in any context, and it has different implications for how intimacy might be approached and structured in a relationship.

Genitourinary Syndrome of Menopause — and Local Oestrogen

GSM is one of the most undertreated conditions in women's health — not because it is difficult to treat, but because women do not raise it and clinicians do not ask about it. The combination of social discomfort around discussing genitourinary symptoms and the cultural assumption that these changes are an inevitable part of ageing that must be accepted produces a situation where many women live with significant symptoms unnecessarily.

Local vaginal oestrogen is the most effective treatment for GSM, and it is available on NHS prescription. It is applied directly to vaginal tissue as a cream, pessary, ring, or tablet. The amount of oestrogen that enters the systemic circulation from local vaginal oestrogen is minimal — substantially less than from any systemic HRT preparation. This means it carries a very different risk profile from systemic HRT: it is appropriate for the vast majority of women, including most of those who have been told they cannot take systemic HRT because of breast cancer history or other concerns. It is not the same treatment as systemic HRT, and it should not be assessed as if it were.

Despite this, local vaginal oestrogen is dramatically underused. It is not routinely discussed at perimenopause consultations. Many women are unaware it exists. And many GPs who would comfortably prescribe systemic HRT are uncertain about local oestrogen prescribing for women with a history of hormone-sensitive cancers, even though the clinical guidance in most cases supports its use. If you are experiencing genitourinary symptoms, you are entitled to ask specifically about local vaginal oestrogen — and if there are concerns about your eligibility, to ask for a specific clinical explanation of those concerns.

Testosterone Therapy for Women

Testosterone therapy for women is licensed in the UK for hypoactive sexual desire disorder — low sexual desire that causes distress to the woman experiencing it. It is prescribed as a gel or cream applied to the skin, and requires blood level monitoring to ensure appropriate dosing and to prevent supraphysiological levels.

Beyond libido, testosterone therapy has documented effects on energy, brain fog, mood, and muscle maintenance — effects that are relevant to many women during perimenopause independently of sexual concerns. Many women who are prescribed testosterone for libido report that energy and cognitive improvements are among the most noticeable effects.

Despite being licensed, testosterone for women is not universally available or prescribed in NHS primary care. Awareness and familiarity with prescribing for women is higher in specialist menopause clinics than in general practice. If you are interested in discussing testosterone, asking specifically — "I'd like to discuss testosterone therapy — is this something we could explore?" — is a more effective approach than waiting for it to be raised proactively.

Having the Conversation — With Your GP and With a Partner

The conversations that most women with perimenopause-related sexual and intimacy changes are not having — with their GPs and with their partners — are the most important conversations for addressing the situation effectively.

With your GP, the conversation does not require clinical language or elaborate framing. "Things have changed physically in my intimate life and I'd like to talk about it" is sufficient. If that feels too vague: "I've noticed changes in desire, physical comfort, and lubrication that are affecting my intimate relationship and I want to understand what's causing them and whether there is treatment available." A GP who is not responsive to this framing, or who dismisses the concern, should be asked specifically whether local oestrogen and testosterone have been considered.

With a partner, the conversation is harder but often more important — because the silence around these changes frequently produces misinterpretation on both sides. Partners who do not know that their partner's desire has changed hormonally tend to attribute the change to relationship factors: to reduced attraction, to emotional withdrawal, to dissatisfaction. The conversation that addresses this directly — "my desire has changed because of perimenopause, not because of how I feel about you" — is one of the most relationship-protective conversations available.